Cell surface proteomics: analytical challenges and clinical applications in cancer

Laurent, Anna; Allard, Adrien; Fillet, Marianne

doi:10.1016/j.trac.2025.118143

Request a copy

Article (Scientific journals)

Cell surface proteomics: analytical challenges and clinical applications in cancer

Laurent, Anna; Allard, Adrien; Fillet, Marianne

2025 • In TrAC: Trends in Analytical Chemistry, p. 118143

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/327089

DOI
10.1016/j.trac.2025.118143

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Cell surface proteomics _ Anna Laurent.pdf

Embargo Until 01/Mar/2027 - Author postprint (671.25 kB)

Creative Commons License - Attribution, Non-Commercial, No Derivative

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cell surface proteomics; mass spectrometry acquisition mode; sample preparation; liquid chromatography; capillary electrophoresis; cancer

Abstract :

[en] Cell surface protein study has shown growing interest in the past few years in the medical and pharmaceutical community. Indeed, due to their easy accessibility, they represent the largest category of drug targets today. Nevertheless, their analysis and characterization remain challenging due to their poor solubility, cleavability, and abundance, as well as their higher aggregability and glycosylation. This review presents current and innovative strategies for cell surface protein extraction, such as innovative biotinylation-based strategies, cell sorting-based strategies, nanodiscs strategies, hydrazide-chemistry-based strategies or enzyme-based and spatially restricted strategies. It also presents analytical workflows innovations applicable to cell surface protein analysis such as using liquid chromatography (i.e. nanoflow micropillar array columns - PAC), and/or capillary electrophoresis coupled with innovative mass spectrometry data acquisition modes. Finally, this review gives some illustrations of the interest of surfacome studies in the field of cancer research.

Research Center/Unit :

CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Laurent, Anna ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)

Allard, Adrien ; Université de Liège - ULiège > Faculté de Médecine > Master sc. pharma., fin. spéc. conc. & dév. méd. - bioana.

Fillet, Marianne ; Université de Liège - ULiège > Département de pharmacie > Analyse des médicaments ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)

Language :

English

Title :

Cell surface proteomics: analytical challenges and clinical applications in cancer

Publication date :

January 2025

Journal title :

TrAC: Trends in Analytical Chemistry

ISSN :

0165-9936

eISSN :

1879-3142

Publisher :

Elsevier BV

Pages :

118143

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://api.elsevier.com/content/article/PII:S0165993625000111?httpAccept=text/xml

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique

Funding number :

40016808

Available on ORBi :

since 20 January 2025

Statistics

Number of views

15 (7 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Al-Amrani, S., Al-Jabri, Z., Al-Zaabi, A., Alshekaili, J., Al-Khabori, M., Proteomics: concepts and applications in human medicine. WJBC 12:5 (Sep. 2021), 57–69, 10.4331/wjbc.v12.i5.57.
Bausch-Fluck, D., et al. A mass spectrometric-derived cell surface protein Atlas. PLoS One, 10(4), Apr. 2015, e0121314, 10.1371/journal.pone.0121314.
Ferguson, I.D., et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat. Commun., 13(1), Jul. 2022, 4121, 10.1038/s41467-022-31810-6.
Nix, M.A., et al. Surface proteomics reveals CD72 as a target for in vitro –evolved nanobody-based CAR-T cells in KMT2A/MLL1 -rearranged B-ALL. Cancer Discov. 11:8 (Aug. 2021), 2032–2049, 10.1158/2159-8290.CD-20-0242.
Nix, C., Hemmati, M., Cobraiville, G., Servais, A.-C., Fillet, M., Blood microsampling to monitor metabolic profiles during physical exercise. Front. Mol. Biosci., 8, May 2021, 681400, 10.3389/fmolb.2021.681400.
Kuhlmann, L., Cummins, E., Samudio, I., Kislinger, T., Cell-surface proteomics for the identification of novel therapeutic targets in cancer. Expet Rev. Proteonomics 15:3 (Mar. 2018), 259–275, 10.1080/14789450.2018.1429924.
Syafruddin, S.E., Nazarie, W.F.W.M., Moidu, N.A., Soon, B.H., Mohtar, M.A., Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature. BMC Cancer, 21(1), Dec. 2021, 850, 10.1186/s12885-021-08591-0.
Kalxdorf, M., et al. Cell surface thermal proteome profiling tracks perturbations and drug targets on the plasma membrane. Nat. Methods 18:1 (Jan. 2021), 84–91, 10.1038/s41592-020-01022-1.
Prados-Rosales, R.C., Aragoneses-Cazorla, G., Estevez, H., Garcia-Calvo, E., Machuca, A., Luque-Garcia, J.L., Strategies for membrane protein analysis by mass spectrometry. Woods, A.G., Darie, C.C., (eds.) Advancements of Mass Spectrometry in Biomedical Research Advances in Experimental Medicine and Biology, vol. 1140, 2019, Springer International Publishing, Cham, 289–298, 10.1007/978-3-030-15950-4_16 1140.
Leung, K.K., Wilson, G.M., Kirkemo, L.L., Riley, N.M., Coon, J.J., Wells, J.A., Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes. Proc. Natl. Acad. Sci. U.S.A. 117:14 (Apr. 2020), 7764–7775, 10.1073/pnas.1917947117.
Rose, M., et al. Surfaceome proteomic of glioblastoma revealed potential targets for immunotherapy. Front. Immunol., 12, Sep. 2021, 746168, 10.3389/fimmu.2021.746168.
Haverland, N.A., Waas, M., Ntai, I., Keppel, T., Gundry, R.L., Kelleher, N.L., Cell surface proteomics of N-linked glycoproteins for typing of human lymphocytes. Proteomics, 17(19), Oct. 2017, 1700156, 10.1002/pmic.201700156.
Bausch-Fluck, D., Hofmann, A., Wollscheid, B., Cell surface capturing technologies for the surfaceome discovery of hepatocytes. Josic, D., Hixson, D.C., (eds.) Liver Proteomics Methods in Molecular Biology, vol. 909, 2012, Humana Press, Totowa, NJ, 1–16, 10.1007/978-1-61779-959-4_1 909.
Santos, R., et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16:1 (Jan. 2017), 19–34, 10.1038/nrd.2016.230.
Vilen, Z., Reeves, A.E., O'Leary, T.R., Joeh, E., Kamasawa, N., Huang, M.L., Cell surface engineering enables surfaceome profiling. ACS Chem. Biol. 18:4 (Apr. 2023), 701–710, 10.1021/acschembio.1c00865.
Ayaz-Guner, S., et al. Protocol for cell surface biotinylation of magnetic labeled and captured human peripheral blood mononuclear cells. STAR Protocols, 3(4), Dec. 2022, 101863, 10.1016/j.xpro.2022.101863.
Ulmschneider, M.B., Sansom, M.S.P., Amino acid distributions in integral membrane protein structures. Biochim. Biophys. Acta Biomembr. 1512:1 (May 2001), 1–14, 10.1016/S0005-2736(01)00299-1.
Zhang, X., Less is more: membrane protein digestion beyond urea–trypsin solution for next-level proteomics. Mol. Cell. Proteomics 14:9 (Sep. 2015), 2441–2453, 10.1074/mcp.R114.042572.
Li, M., et al. Coupling of cell surface biotinylation and SILAC-based quantitative proteomics identified myoferlin as a potential therapeutic target for nasopharyngeal carcinoma metastasis. Front. Cell Dev. Biol., 9, Jun. 2021, 621810, 10.3389/fcell.2021.621810.
Elschenbroich, S., Kim, Y., Medin, J.A., Kislinger, T., Isolation of cell surface proteins for mass spectrometry-based proteomics. Expet Rev. Proteonomics 7:1 (Feb. 2010), 141–154, 10.1586/epr.09.97.
Lejeune, M., et al. Integrative analysis of proteomics and transcriptomics reveals endothelin receptor B as novel single target and identifies new combinatorial targets for multiple myeloma. HemaSphere, 7(7), Jul. 2023, e901, 10.1097/HS9.0000000000000901.
Anderson, G.S.F., et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood 139:16 (Apr. 2022), 2471–2482, 10.1182/blood.2021015161.
Lager, T.W., Conner, C., Keating, C.R., Warshaw, J.N., Panopoulos, A.D., Cell surface GRP78 and Dermcidin cooperate to regulate breast cancer cell migration through Wnt signaling. Oncogene 40:23 (Jun. 2021), 4050–4059, 10.1038/s41388-021-01821-6.
Chen, W., Mou, K.Y., Solomon, P., Aggarwal, R., Leung, K.K., Wells, J.A., Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. Proc. Natl. Acad. Sci. U.S.A., 118(4), Jan. 2021, e2018861118, 10.1073/pnas.2018861118.
Sun, F., Suttapitugsakul, S., Wu, R., Unraveling the surface glycoprotein interaction network by integrating chemical crosslinking with MS-based proteomics. Chem. Sci. 12:6 (2021), 2146–2155, 10.1039/D0SC06327D.
Byrnes, J.R., et al. Hypoxia is a dominant remodeler of the effector T cell surface proteome relative to activation and regulatory T cell suppression. Mol. Cell. Proteomics, 21(4), Apr. 2022, 100217, 10.1016/j.mcpro.2022.100217.
Kirkemo, L.L., et al. Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells. Elife, 11, Mar. 2022, e73982, 10.7554/eLife.73982.
Hwang, J., Espenshade, P.J., Proximity-dependent biotin labelling in yeast using the engineered ascorbate peroxidase APEX2. Biochem. J. 473:16 (Aug. 2016), 2463–2469, 10.1042/BCJ20160106.
Hung, V., et al. Spatially resolved proteomic mapping in living cells with the engineered peroxidase APEX2. Nat. Protoc. 11:3 (Mar. 2016), 456–475, 10.1038/nprot.2016.018.
Sears, R.M., May, D.G., Roux, K.J., BioID as a tool for protein-proximity labeling in living cells. Nuijens, T., Schmidt, M., (eds.) Enzyme-Mediated Ligation Methods Methods in Molecular Biology, vol. 2012, 2019, Springer, New York, 299–313, 10.1007/978-1-4939-9546-2_15 2012., New York, NY.
Takano, T., Soderling, S.H., Tripartite synaptomics: cell-surface proximity labeling in vivo. Neurosci. Res. 173 (Dec. 2021), 14–21, 10.1016/j.neures.2021.05.002.
Motani, K., Kosako, H., BioID screening of biotinylation sites using the avidin-like protein Tamavidin 2-REV identifies global interactors of stimulator of interferon genes (STING). J. Biol. Chem. 295:32 (Aug. 2020), 11174–11183, 10.1074/jbc.RA120.014323.
Nishino, K., Yoshikawa, H., Motani, K., Kosako, H., Optimized workflow for enrichment and identification of biotinylated peptides using Tamavidin 2-REV for BioID and cell surface proteomics. J. Proteome Res. 21:9 (Sep. 2022), 2094–2103, 10.1021/acs.jproteome.2c00130.
Tremblay, T.-L., Fauteux, F., Callaghan, D., Hill, J.J., Cell surface profiling of cultured cells by direct hydrazide capture of oxidized glycoproteins. MethodsX, 11, Dec. 2023, 102349, 10.1016/j.mex.2023.102349.
Seyfrid, M., et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. J. Immunother. Cancer, 10(1), Jan. 2022, e003289, 10.1136/jitc-2021-003289.
Sligar, S.G., Denisov, I.G., Nanodiscs: a toolkit for membrane protein science. Protein Sci. 30:2 (Feb. 2021), 297–315, 10.1002/pro.3994.
Pettersen, J.M., Yang, Y., Robinson, A.S., Advances in nanodisc platforms for membrane protein purification. Trends Biotechnol. 41:8 (Aug. 2023), 1041–1054, 10.1016/j.tibtech.2023.02.006.
Elia, G., Biotinylation reagents for the study of cell surface proteins. Proteomics 8:19 (Oct. 2008), 4012–4024, 10.1002/pmic.200800097.
Elia, G., Protein biotinylation. CP Protein Sci., 60(1), Apr. 2010, 10.1002/0471140864.ps0306s60.
Kuhlmann, L., et al. Glycoproteomics identifies Plexin-B3 as a targetable cell surface protein required for the growth and invasion of triple-negative breast cancer cells. J. Proteome Res. 21:9 (Sep. 2022), 2224–2236, 10.1021/acs.jproteome.2c00332.
Özkan Küçük, N.E., Şanal, E., Tan, E., Mitchison, T., Özlü, N., Labeling carboxyl groups of surface-exposed proteins provides an orthogonal approach for cell surface isolation. J. Proteome Res. 17:5 (May 2018), 1784–1793, 10.1021/acs.jproteome.7b00825.
Köhnke, T., et al. Integrated multiomic approach for identification of novel immunotherapeutic targets in AML. Biomark. Res., 10(1), Dec. 2022, 43, 10.1186/s40364-022-00390-4.
Takano, T., et al. Chemico-genetic discovery of astrocytic control of inhibition in vivo. Nature 588:7837 (Dec. 2020), 296–302, 10.1038/s41586-020-2926-0.
Zhang, F., Ge, W., Ruan, G., Cai, X., Guo, T., Data‐independent acquisition mass spectrometry‐based proteomics and software tools: a glimpse in 2020. Proteomics, 20(17–18), Sep. 2020, 1900276, 10.1002/pmic.201900276.
Matzinger, M., Mayer, R.L., Mechtler, K., Label‐free single cell proteomics utilizing ultrafast LC and MS instrumentation: a valuable complementary technique to multiplexing. Proteomics, 23(13–14), Jul. 2023, 2200162, 10.1002/pmic.202200162.
Ishikawa, M., et al. Optimization of ultrafast proteomics using an LC-quadrupole-orbitrap mass spectrometer with data-independent acquisition. J. Proteome Res. 21:9 (Sep. 2022), 2085–2093, 10.1021/acs.jproteome.2c00121.
Nys, G., Mass Spectrometry Supported by Microsampling and Microfluidics: Application to Complex Biomedical Challenges. 2019, Université de Liège.
Mendes, M.L., Dittmar, G., Targeted proteomics on its way to discovery. Proteomics, 22(15–16), Aug. 2022, 2100330, 10.1002/pmic.202100330.
Gillet, L.C., et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics, 11(6), Jun. 2012, 016717, 10.1074/mcp.O111.016717 O111.
Bekker-Jensen, D.B., et al. A compact quadrupole-orbitrap mass spectrometer with FAIMS interface improves proteome coverage in short LC gradients. Mol. Cell. Proteomics 19:4 (Apr. 2020), 716–729, 10.1074/mcp.TIR119.001906.
Meier, F., et al. Parallel accumulation–serial fragmentation (PASEF): multiplying sequencing speed and sensitivity by synchronized scans in a trapped ion mobility device. J. Proteome Res. 14:12 (Dec. 2015), 5378–5387, 10.1021/acs.jproteome.5b00932.
Meier, F., Park, M.A., Mann, M., Trapped ion mobility spectrometry and parallel accumulation–serial fragmentation in proteomics. Mol. Cell. Proteomics, 20, 2021, 100138, 10.1016/j.mcpro.2021.100138.
Ludwig, C., Gillet, L., Rosenberger, G., Amon, S., Collins, B.C., Aebersold, R., Data‐independent acquisition‐based SWATH ‐ MS for quantitative proteomics: a tutorial. Mol. Syst. Biol., 14(8), Aug. 2018, e8126, 10.15252/msb.20178126.
Messner, C.B., et al. Scanning SWATH acquisition enables high-throughput proteomics with chromatographic gradients as fast as 30 seconds. Syst. Biol., preprint, May 2019, 10.1101/656793.
Messner, C.B., et al. Ultra-fast proteomics with scanning SWATH. Nat. Biotechnol. 39:7 (Jul. 2021), 846–854, 10.1038/s41587-021-00860-4.
Dodds, J.N., Baker, E.S., Ion mobility spectrometry: fundamental concepts, instrumentation, applications, and the road ahead. J. Am. Soc. Mass Spectrom. 30:11 (Nov. 2019), 2185–2195, 10.1007/s13361-019-02288-2.
Meier, F., Park, M.A., Mann, M., Trapped ion mobility spectrometry and parallel accumulation–serial fragmentation in proteomics. Mol. Cell. Proteomics, 20, 2021, 100138, 10.1016/j.mcpro.2021.100138.
Meier, F., et al. diaPASEF: parallel accumulation–serial fragmentation combined with data-independent acquisition. Nat. Methods 17:12 (Dec. 2020), 1229–1236, 10.1038/s41592-020-00998-0.
Skowronek, P., et al. Synchro-PASEF allows precursor-specific fragment ion extraction and interference removal in data-independent acquisition. Mol. Cell. Proteomics, 22(2), Feb. 2023, 100489, 10.1016/j.mcpro.2022.100489.
Szyrwiel, L., Sinn, L., Ralser, M., Demichev, V., “Slice-PASEF: Fragmenting All Ions for Maximum Sensitivity in Proteomics,”. Oct. 31, 2022, 10.1101/2022.10.31.514544.
Charkow, J., Röst, H.L., Trapped ion mobility spectrometry reduces spectral complexity in mass spectrometry-based proteomics. Anal. Chem. 93:50 (Dec. 2021), 16751–16758, 10.1021/acs.analchem.1c01399.
Yang, Z., Shen, X., Chen, D., Sun, L., Improved nanoflow RPLC-CZE-MS/MS system with high peak capacity and sensitivity for nanogram bottom-up proteomics. J. Proteome Res. 18:11 (Nov. 2019), 4046–4054, 10.1021/acs.jproteome.9b00545.
Vankeerberghen, B., Op De Beeck, J., Desmet, G., On-chip comparison of the performance of first- and second-generation micropillar array columns. Anal. Chem. 95:37 (Sep. 2023), 13822–13828, 10.1021/acs.analchem.3c01829.
Nix, C., Cobraiville, G., Gou, M.-J., Fillet, M., Potential of single pulse and multiplexed drift-tube ion mobility spectrometry coupled to micropillar array column for proteomics studies. Indian J. Manag. Sci., 23(14), Jul. 2022, 7497, 10.3390/ijms23147497.
Matzinger, M., et al. Micropillar arrays, wide window acquisition and AI-based data analysis improve comprehensiveness in multiple proteomic applications. Nat. Commun., 15(1), Feb. 2024, 1019, 10.1038/s41467-024-45391-z.
Vankeerberghen, B., Op De Beeck, J., Desmet, G., Column-only band broadening in a porous shell radially elongated pillar array column. Anal. Chem. 96:8 (Feb. 2024), 3618–3626, 10.1021/acs.analchem.3c05756.
Gou, M.-J., et al. Contribution of capillary zone electrophoresis hyphenated with drift tube ion mobility mass spectrometry as a complementary tool to microfluidic reversed phase liquid chromatography for antigen discovery. Indian J. Manag. Sci., 23(21), Nov. 2022, 13350, 10.3390/ijms232113350.
Yang, Z., Shen, X., Chen, D., Sun, L., Microscale reversed-phase liquid chromatography/capillary zone electrophoresis-tandem mass spectrometry for deep and highly sensitive bottom–up proteomics: identification of 7500 proteins with five micrograms of an MCF7 proteome digest. Anal. Chem. 90:17 (Sep. 2018), 10479–10486, 10.1021/acs.analchem.8b02466.
Latosinska, A., Siwy, J., Mischak, H., Frantzi, M., Peptidomics and proteomics based on CE‐MS as a robust tool in clinical application: the past, the present, and the future. Electrophoresis 40:18–19 (Sep. 2019), 2294–2308, 10.1002/elps.201900091.
Pontillo, C., Filip, S., Borràs, D.M., Mullen, W., Vlahou, A., Mischak, H., CE‐MS‐based proteomics in biomarker discovery and clinical application. Proteom. Clin. Apps 9:3–4 (Apr. 2015), 322–334, 10.1002/prca.201400115.
World Health Organization. Cancer (Feb 2022) [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/cancer.
Int. Agen. Res. Cancer. Population factsheets (2022) [Online]. Available: https://gco.iarc.who.int/today/en/fact-sheets-populations.
Di Meo, F., et al. Mapping the high-risk multiple myeloma cell surface proteome identifies T-cell inhibitory receptors for immune targeting. Blood, 138(Supplement 1), Nov. 2021, 10.1182/blood-2021-147483 265–265.
Chen, L., Qin, D., Guo, X., Wang, Q., Li, J., Putting proteomics into immunotherapy for glioblastoma. Front. Immunol., 12, Feb. 2021, 593255, 10.3389/fimmu.2021.593255.
Ge, H., et al. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. Int. J. Cancer 141:7 (Oct. 2017), 1434–1444, 10.1002/ijc.30830.
Diegmann, J., Junker, K., Loncarevic, I.F., Michel, S., Schimmel, B., Von Eagelinq, F., Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 8:11 (Nov. 2006), 933–938, 10.1593/neo.06451.
Inaguma, S., et al. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J. Pathol. 250:2 (Feb. 2020), 205–216, 10.1002/path.5361.
Nilsson, M.B., et al. CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell 41:2 (Feb. 2023), 340–355.e6, 10.1016/j.ccell.2023.01.007.
Nath, S., Devi, G.R., Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol. Therapeut. 163 (Jul. 2016), 94–108, 10.1016/j.pharmthera.2016.03.013.
Shi, H., et al. Myoferlin disturbs redox equilibrium to accelerate gastric cancer migration. Front. Oncol., 12, Sep. 2022, 905230, 10.3389/fonc.2022.905230.
Rademaker, G., et al. Myoferlin targeting triggers mitophagy and primes ferroptosis in pancreatic cancer cells. Redox Biol., 53, Jul. 2022, 102324, 10.1016/j.redox.2022.102324.
Pi, R., Chen, Y., Du, Y., Dong, S., Comprehensive analysis of myoferlin in human pancreatic cancer via bioinformatics. BioMed Res. Int. 2021 (Dec. 2021), 1–17, 10.1155/2021/2602322.
He, Y., et al. A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression. Clin. Transl. Med., 11(2), Feb. 2021, e289, 10.1002/ctm2.289.
Qian, T., et al. PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis. Oncogene 39:10 (Mar. 2020), 2069–2087, 10.1038/s41388-019-1135-5.
Zuo, Q., et al. Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis. Cell Rep., 42(3), Mar. 2023, 112164, 10.1016/j.celrep.2023.112164.
Semenza, G.L., Mechanisms of breast cancer stem cell specification and self-renewal mediated by hypoxia-inducible factor 1. Stem. Cells Translat. Med. 12:12 (Dec. 2023), 783–790, 10.1093/stcltm/szad061.
Lester, D.K., et al. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat. Can. (Ott.) 4:2 (Jan. 2023), 222–239, 10.1038/s43018-022-00506-7.
Capdeville, C., et al. Spatial proteomics finds CD155 and Endophilin-A1 as mediators of growth and invasion in medulloblastoma. Life Sci. Alliance, 5(6), Jun. 2022, e202201380, 10.26508/lsa.202201380.
Conner, C., et al. Cell surface GRP78 promotes stemness in normal and neoplastic cells. Sci. Rep., 10(1), Feb. 2020, 3474, 10.1038/s41598-020-60269-y.
“UniProt,” UniProt. [Online]. Available: https://www.uniprot.org.